logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Pharmaceutical
Filter

Pharmaceutical

Categories

Sectors

Locations

Exchange

FDA Delays Lilly’s Weight-Loss Pill: Is the Stock Still a Buy for 2026?

FDA Delays Lilly’s Weight-Loss Pill: Is the Stock Still a Buy for 2026?

Jan 25, 2026

Life Science

The 2026 AI Stock Showdown: Can Alphabet Outperform Microsoft Again?

Two Healthcare Companies Are Planning for the Long Term with AI 

Jan 23, 2026

Life Science

投资AI浪潮:英伟达与Palantir的成长机遇

This International ETF Outperformed the S&P 500

Jan 23, 2026

Life Science, Technology

股价翻倍之后:阿里巴巴的AI故事才刚刚开始?

Prospects for a Strong Rebound by Two Healthcare Giants: Zoetis and Regeneron Pharmaceuticals 

Jan 22, 2026

Life Science

宏观隐忧下的盈利信心:华尔街看好美股长期牛市

Decoding the Gene Editing Sector and Focusing on Progress and Investment Perspectives of Three Leading Companies 

Jan 21, 2026

Life Science

美银展望2026,称AI热潮驱动半导体产业迈向万亿美元大关

Can Viking Therapeutics Make a Turnaround This Year?

Jan 21, 2026

Life Science

Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities

Massive Upside Potential: Two Canadian Growth Stocks for Risk-Tolerant Investors

Jan 21, 2026

Life Science, Precious Metals

Is Pfizer’s Turnaround Story Worth a Closer Look?

GSK to Acquire RAPT Therapeutics for $2.2 Billion, Bolstering Food Allergy Pipeline

Jan 20, 2026

Life Science

从英伟达到博通,解析美银2026年半导体优选清单

The Long-Term Investment Value of Eli Lilly, AbbVie, and Intuitive Surgical

Jan 20, 2026

Life Science

Can Zumilokibart Become the Next Megablockbuster? Inside AbbVie’s $10.9 Billion Bet on Apogee

French Biotech Abivax Soared 1,740% Last Year. Can the Rally Continue?

Jan 19, 2026

Life Science

逆风上涨417%,Opendoor的转型赌注能否成功?

NVIDIA and Eli Lilly Team Up to Open a New Chapter in AI-Driven Drug Development

Jan 16, 2026

Life Science, Technology

Credit Spread Fever: HYG, LQD Flash 2007 Vibes

Jan 16, 2026

Life Science, Technology

American Express Trades Below 20 P/E — Is Buffett’s Second-Largest Bet Now a Steal?

Forward P/E Highlights Undervalued Growth Opportunities in ABBV, MU and ADBE

Jan 15, 2026

Life Science, Technology

GSK Pays 40% Premium to Buy Nuvalent in Major Oncology Push

ImmunityBio Soars Over 30% as Bladder Cancer Drug Anktiva Delivers Breakout Growth

Jan 15, 2026

Life Science

2025年值得关注的三只金融科技股票

Three Promising Healthcare Stocks Poised to Maintain Their Leadership Position

Jan 14, 2026

Life Science

5 Pharma Stocks Offering 3%+ Dividend Yields for Uncertain Times

5 Pharma Stocks Offering 3%+ Dividend Yields for Uncertain Times

Jan 14, 2026

Life Science

回调中的白银在2026年是否迎来配置机遇?

UnitedHealth Faces Short-Term Pressure but Maintains Long-Term Potential 

Jan 14, 2026

Life Science

After a 57% Rally, Is UnitedHealth Group Still a Buy?

Eli Lilly and Novo Nordisk: The Battle for Dominance in the 2026 Weight-Loss Drug Market

Jan 13, 2026

Life Science

  • ‹‹ Previous
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada